Updated on 4 March 2015
Taiho Pharma Europe Ltd., a subsidiary of Japan-based Taiho Pharmaceutical, has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for TAS-102, an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC).
TAS-102 is an oral combination investigational anti-cancer drug of trifluridine (FTD) and tipiracil hydrochloride (TPI). FTD is an anti-neoplastic nucleoside analog, which is incorporated directly into DNA, thereby interfering with the function of DNA. The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase.
This MAA submission closely follows the TAS-102 New Drug Application (NDA) submission to the US Food and Drug Administration (FDA), which was accepted for review by the FDA on February 17, 2015. TAS-102 was approved initially in Japan in March 2014 and launched in May 2014 under the brand name Lonsurf combination tablet T15, T20.
The MAA submission is supported by the results of the randomized, double-blind, placebo-controlled, Phase III RECOURSE trial of TAS-102 in 800 mCRC patients, whose disease had progressed after or who were intolerant to standard therapies.
The TAS-102 RECOURSE trial met the primary efficacy endpoint of statistically significant improvement in overall survival versus placebo (HR = 0.68, p < 0.0001) and demonstrated a safety profile consistent with that observed in earlier clinical trials.